

Special Issue

Advancements and Treatment Strategies for Central Nervous System Malignancies and Cancer Stem Cells

Message from the Guest Editor

This Special Issue aims to include cutting-edge research and reviews that enhance our understanding of the molecular mechanisms behind central nervous system malignancies and the crucial role of cancer stem cells (CSCs) in the initiation, progression, and resistance to the treatment of these malignancies. We are inviting contributions on a range of topics, including the identification of new biomarkers, the elucidation of signaling pathways, the examination of the tumor microenvironment, the mechanisms underlying resistance to therapy, and the development of targeted treatments. This Special Issue aims to present the most recent discoveries and experimental technologies in the biology of central nervous system malignancies. Our goal is to provide a comprehensive understanding of this field and to support the use of these findings in the development of successful clinical treatments. Our Special Issue will include original research articles, reviews, systematic reviews, communications, commentaries, opinions, and perspective pieces.

Guest Editor

Dr. Mingli Liu

Department Microbiology, Biochemistry & Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA

Deadline for manuscript submissions

closed (30 September 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/213325

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)